ArticleJournal of thoracic disease2026
External validation of the eurolung risk model for morbidity using an institutional database on minimally invasive major lung resections.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The EuroLung1 model was developed by the European Society of Thoracic Surgeons (ESTS) to estimate the risk of major cardiopulmonary complications after anatomical lung resection. Because minimally invasive approaches were underrepresented in the original derivation cohort, its performance in contemporary thoracoscopic practice remains uncertain. We therefore conducted an external validation using a cohort of patients undergoing minimally invasive major lung resection. Methods: This retrospective study included 644 consecutive patients (293 females and 351 males; median age, 66 years) treated with thoracoscopic lobectomy or segmentectomy. For each patient, the EuroLung1 score was determined according to the published scoring algorithm incorporating eight weighted clinical and operative variables. Patients were subsequently categorized into the predefined risk classes. Associations between the score and major morbidity were examined, while model discrimination and calibration were evaluated using standard validation metrics. Results: The cohort included 574 lobectomies (89.1%) and 70 segmentectomies (10.9%). Histopathology revealed 548 patients (85.1%) with confirmed non-small cell lung cancer (NSCLC), 66 (10.2%) with benign disease, and 30 (4.7%) with pulmonary metastasis. Postoperative mortality and major complication rates were 0.9% and 12.9%, respectively. In logistic regression analysis, each 1-point increase in the EuroLung1 score was associated with 9% higher odds of morbidity [odds ratio (OR) =1.092, 95% confidence interval (CI): 1.010-1.180, P=0.03]. Similarly, advancing by one risk class conferred a 33% increase in the odds (OR =1.327, 95% CI: 1.027-1.715, P=0.03). Calibration analysis revealed that the EuroLung1 score underestimated morbidity risk in lower-risk classes and overestimated it in higher-risk classes. Discrimination performance of EuroLung1 score was poor, with an area under the receiver operating characteristic (ROC) curve of 0.573. Conclusions: Although the EuroLung1 score retained a significant relationship with postoperative major morbidity after minimally invasive anatomical lung resection, its predictive performance was suboptimal. The weak discrimination and variable calibration observed in this validation cohort suggest that model recalibration or revision may be necessary before application to individual risk estimation in contemporary minimally invasive thoracic surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.